Furthermore, it was demonstrated, in an ectopic xenograft colon cancer model, that administration of CB2 (JWH-133 and HU-308) agonists promoted cancer progression (Martínez-Martínez et al., 2016). This evidence concerns the gene CNR2 and malignant colon neoplasm.